In 2026, the Bosong War broke out early, and the stock price of BOAN BIOTECH (06955), which had been falling for nearly half a year, stabilized and rebounded.

Since reaching a temporary high of 19.90 Hong Kong dollars in the trading session on August 8 last year, the stock price of BOAN BIOTECH (06955) has started a downturn lasting more than 5 months. On January 5 this year, BOAN BIOTECH's stock price reached a new low of 8.15 Hong Kong dollars within the year, making the high and low of this downturn reach 59.05%. It can be observed that due to the uptrend in the first half of last year, even with a market value of only 5.312 billion Hong Kong dollars by the end of last year, BOAN BIOTECH still maintained a daily market value of 6.565 billion Hong Kong dollars within the review period of the second phase of the Hong Kong Stock Connect in 2025, successfully meeting the threshold of 6.026 billion Hong Kong dollars and achieving a successful "connect". However, as a commercialized pharmaceutical company that has achieved profits in three consecutive reporting periods, BOAN BIOTECH's current stock price is less than 6 billion Hong Kong dollars, significantly lower than the next period's "connect water level". As the 2025 annual report approaches, whether the company can resonate with the fundamentals and technical aspects to break out of the downtrend and continue to maintain its position in the Hong Kong Stock Connect may directly affect the allocation direction of secondary market investors. Breaking out of a nearly half-year downtrend in stock prices From a technical perspective, since August of last year, BOAN BIOTECH has been in a downward channel of "price falling, volume shrinking". Overall, after reaching a high point and BOLL upper band on August 8 last year, BOAN BIOTECH's stock price saw a "reversal doji" the next day and began to technically return to the BOLL lower band. The company's stock price continued to fluctuate between the BOLL lower and middle bands for the following 3 months, with market sentiment relatively low. Specifically, BOAN BIOTECH's stock price attempted to pull back to the middle band after first touching the BOLL lower band on August 20 last year, but the lack of volume from off-site holders due to their wait-and-see attitude led to a failed rally. On August 27, the company's stock price failed to touch the BOLL mid band, which to a certain extent triggered internal disagreements the next day, with some holders selling and exiting.